Please wait while the formulary information is being retrieved.
RAYALDEE (CALCIFEDIOL)
- Hyperparathyroidism secondary to chronic renal failure
30 mcg capsule,extended release
- 1 capsule (30 mcg) by oral route once daily at bedtime
Hyperparathyroidism secondary to chronic renal failure
- 1 capsule (30 mcg) by oral route once daily at bedtime
- 2 capsules (60 mcg) by oral route once daily at bedtime
- None
Contraindicated
- None
Severe
Moderate
- None
- Hypervitaminosis D
Contraindicated
- Arteriosclerosis obliterans
- Hypercalcemia
- Hyperphosphatemia
- Kidney stone
Severe
Moderate
- Kidney disease with reduction in GFR
- Sarcoidosis
RAYALDEE (CALCIFEDIOL)
- Hyperparathyroidism secondary to chronic renal failure
- Anemia
- Chronic heart failure
- Constipation
- Dyspnea
- Pharyngitis
More Frequent
Severe
Less Severe
- Chronic obstructive pulmonary disease
- Hyperkalemia
- Pneumonia
- Arthritis
- Bruising
- Hyperuricemia
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Adynamic bone disease
- Hypercalcemia
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Calcifediol
Safety and efficacy not established.
- 1 Day – 18 Years
- Safety and efficacy not established.
Calcifediol
- Severity Level:
2
- Additional Notes: Insufficient human data available on developmental toxicity risk
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Hyperparathyroidism secondary to chronic renal failure | |
| N25.81 | Secondary hyperparathyroidism of renal origin |
| 0-9 | A-Z |
|---|---|
| N25.81 | Secondary hyperparathyroidism of renal origin |
Formulary Reference Tool